Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study

MLA

Rosario Palacios MD, PhD, et al. “Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.” Journal of the International Association of Providers of AIDS Care, vol. 17, Mar. 2018. EBSCOhost, https://doi.org/10.1177/2325958218760847.

APA

Rosario Palacios MD, P., M. Mayorga MD, C. M. González-Domenech PhD, C. Hidalgo-Tenorio MD, P., C. Gálvez MD, P., L. Muñoz-Medina MD, J. de la Torre MD, P., A. Lozano MD, M. Castaño MD, M. Omar MD, P., & Jesús Santos MD, P. (2018). Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study. Journal of the International Association of Providers of AIDS Care, 17. https://doi.org/10.1177/2325958218760847

Chicago

Rosario Palacios MD, PhD, M. Mayorga MD, C. M. González-Domenech PhD, PhD C. Hidalgo-Tenorio MD, PhD C. Gálvez MD, L. Muñoz-Medina MD, PhD J. de la Torre MD, et al. 2018. “Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.” Journal of the International Association of Providers of AIDS Care 17 (March). doi:10.1177/2325958218760847.